If a patient develops restless legs syndrome while taking risperidone, is the likelihood higher that lurasidone will cause the same symptoms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, there is a higher probability that lurasidone will cause restless leg symptoms if a patient developed them with risperidone.

Both risperidone and lurasidone are antipsychotics that can induce restless legs syndrome (RLS) through similar dopaminergic mechanisms, making cross-reactivity likely in susceptible patients.

Understanding the Mechanism

Both medications work by blocking dopamine receptors, which is the primary mechanism by which antipsychotics induce RLS. When a patient develops RLS with one antipsychotic, it indicates they have a vulnerability to dopamine-blocking effects on the pathways involved in RLS pathophysiology 1, 2, 3.

Evidence for Both Medications Causing RLS

Risperidone: Multiple studies confirm risperidone as a known cause of drug-induced RLS. A French pharmacovigilance database study found neuroleptics including risperidone had a reporting odds ratio of 17.8 for RLS 2. Case reports have documented RLS with risperidone that resolved upon switching to alternative agents 1.

Lurasidone: The FDA label explicitly lists "restlessness" as an adverse event occurring in 4% of patients on lurasidone (compared to <1% on placebo) 4. A 2020 risk analysis identified restless leg syndrome as an unlisted adverse reaction with a "probable" causality relationship to lurasidone 5.

Clinical Reasoning

Why Cross-Reactivity is Likely:

  • Shared mechanism: Both drugs antagonize dopamine D2 receptors, the primary pathway for drug-induced RLS
  • Individual susceptibility: Patients who develop RLS with one dopamine antagonist demonstrate a predisposition to this adverse effect
  • Class effect: A 2022 study found 41% of patients receiving antipsychotics developed RLS, suggesting this is a common class-related phenomenon 6

Risk Factors to Consider:

The following increase the likelihood of developing drug-induced RLS 3:

  • Older age
  • Gastrointestinal diseases
  • Higher medication doses
  • Simultaneous use of ≥2 drugs that can cause RLS
  • Family history of RLS 6

Practical Management Algorithm

If your patient developed RLS with risperidone:

  1. First, verify the diagnosis: Ensure symptoms meet RLS criteria (urge to move legs, worse at rest/evening, relieved by movement) and exclude mimicking conditions like akathisia, peripheral neuropathy, or positional discomfort

  2. Consider alternative antipsychotics with lower RLS risk:

    • Quetiapine showed resolution of RLS symptoms in a case where risperidone caused them 1
    • Haloperidol and trazodone were less associated with RLS in one study 6
    • However, note that haloperidol failed to resolve RLS in one case report where risperidone caused it 1
  3. If lurasidone is clinically necessary despite the risk:

    • Use the lowest effective dose (dose-dependent effect documented 4)
    • Monitor closely for RLS symptoms, especially in the first weeks
    • Check iron status (ferritin and transferrin saturation) before starting
    • Consider prophylactic iron supplementation if ferritin <75 ng/mL
  4. If RLS develops on lurasidone:

    • First-line treatment: Gabapentin or pregabalin (strong AASM recommendation) 7
    • Check iron parameters: If ferritin <200 ng/mL and transferrin saturation <20%, use IV ferric carboxymaltose (strong AASM recommendation) 7
    • Avoid dopamine agonists as standard treatment (AASM suggests against due to augmentation risk) 7

Critical Caveats

Do not confuse RLS with akathisia: While both involve restlessness, akathisia is a subjective inner restlessness with motor restlessness affecting the whole body, whereas RLS specifically involves uncomfortable leg sensations worse at rest and in the evening. Polysomnography can help differentiate by documenting periodic limb movements during sleep (PLMS) in RLS 1.

The incidence may be underreported: Lurasidone's FDA label lists "restlessness" rather than specifically "restless legs syndrome," suggesting the true incidence may be higher than documented 4.

Consider the clinical context: If the patient absolutely requires lurasidone for treatment-resistant bipolar depression or schizophrenia where other options have failed, the risk may be acceptable with close monitoring and prophylactic measures. However, given the documented cross-reactivity risk, exploring alternative antipsychotics first is prudent.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.